中国临床药学杂志

参考文献

[1]SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209.

[2]CASTELLANOS E,FELD E,HORN L.Driven by mutations:the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer[J].J Thorac Oncol,2017,12(4):612.

[3]YE L Y,CHEN X X,ZHOU F.EGFR-mutant NSCLC:emerging novel drugs[J].Curr Opin Oncol,2021,33(1):87.

[4]LIN J J,CARDARELLA S,LYDON C A,et al.Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs[J].J Thorac Oncol,2016,11(4):556.

[5]WESTOVER D,ZUGAZAGOITIA J,CHO B C,et al.Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors[J].Ann Oncol,2018,29(Suppl1):i10.

[6]RICORDEL C,FRIB OULET L,FACCHINETTI F,et al.Molecular mechanisms of acquired resistance to third-generation EGFRTKIs in EGFR T790M-mutant lung cancer[J].Ann Oncol,2018,29(suppl 1):i28.

[7]倪莲芳,聂立功.第三代EGFR-TKIs耐药之初探[J].中国肺癌杂志,2018,21(2):110.

[8]陈丽鹃,俞婷婷,单莉.第三代EGFR-TKI获得性耐药相关机制研究[J].医学综述,2020,26(5):888.

[9]KNEBEL F H,BETTONI F,SHIMADA A K,et al.Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC[J].Lung Cancer,2017,108:238.

[10]NUKAGA S,YASUDA H,TSUCHIHARA K,et al.Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors[J].Cancer Res,2017,77(8):2078.

[11]WATANABE S,GOTO Y, YASUDA H,et al.HSP90 inhibition overcomes EGFR amplification-induced resistance to thirdgeneration EGFR-TKIs[J].Thorac Cancer,2021,12(5):631.

[12]ZHAO S,LI X F,ZHAO C,et al.Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M[J].Lung Cancer,2019, 128:33.

[13]TAKEZAWA K,PIRAZZOLI V,ARCILA M E,et al.HER2amplification:a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation[J].Cancer Discov,2012,2(10):922.

[14]RAMALINGAM S S,YANG J C H,LEE C K,et al.Osimertinib as first-line treatment of EGFR mutation-positive advanced nonsmall-cell lung cancer[J].J Clin Oncol,2018,36(9):841.

[15] De LANGEN A J,JEBBINK M,HASHEMI S M S,et al.Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment[J].Br J Cancer,2018,119(5):558.

[16]LA MONICA S,CRETELLA D, BONELLI M,et al.Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines[J].J Exp Clin Cancer Res,2017,36(1):174.

[17]WANG S E.NARASANNA A,PEREZ-TORRES M,et al.HER2kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors[J].Cancer Cell,2006,10(1):25.

[18]WU Y L,CHENG Y,ZHOU J Y,et al.Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor(INSIGHT study):an open-label,phase1b/2,multicentre,randomised trial[J].Lancet Respir Med,2020,8(11):1132.

[19]YANO S,WANG W,LI Q,et al,Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations[J].Cancer Res,2008,68(22):9479.

[20]YANO S,YAMADA T,TAKEUCHI S,et al,Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic[J].J Thorac Oncol,2011,6(12):2011.

[21]PELED N.WYNES M W,IKEDA N,et al.Insulin-like growth factor-1 receptor(IGF-1R)as a bio marker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer[J].Cell Oncol(Dordr),2013,36(4):277.

[22]LEE Y,WANG Y A,JAMES M,et al.Inhibition of IGF1R signaling abrogates resistance to afatinib(BIBW2992)in EGFR T790M mutant lung cancer cells[J].Mol Carcinog,2016,55(5):991.

[23]HAYAKAWA D,TAKAHASHI F,MITSUISHI Y,et al.Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation[J].Thorac Cancer,2020,11(1):140.

[24]MANABE T,YASUDA H,TERAI H,et al,IGF2 autocrinemediated IGFIR activation is a clinically relevant mechanism of osimertinib resistance in lung cancer[J].Mol Cancer Res.2020,18(4):549.

[25]DESAI A,ADJEI A A,FGFR signaling as a target for lung cancer therapy[J].J Thorac Oncol,2016,11(1):9.

[26]RAOOF S,MULFORD I J, FRISCO-CABANOS H,et al.Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant nonsmall cell lung cancer[J].Oncogene,2019,38(3 7):6399.

[27]LOTSBERG M L,WNUK-LIPINSKA K,TERRY S,et al.AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells[J].J Thorac Oncol,2020,15(6):973.

[28]YONESAKA K,TAKEGAWA N,WATANABE S,et al.An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC[J].Oncogene,2019,38(9);1398.

[29]NILSSON M B,ROBICHAUX J.HERYNK M H,et al.Altered regulation of HIF-la in naive-and drug-resistant EGFR-mutant NSCLC:implications for a vascular endothelial growth factordependent phenotype[J].J Thorac Oncol,2021,16(3):439.

[30]YANG Y H, WANG W,CHANG H, et al.Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells[J].J Cell Mol Med, 2019,23(11):7331.

[31]CHEUNG H W,DU J Y,BOEHM J S,et al.Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers[J].Cancer Discov,2011,1(7):608.

[32]DENG Q F,SU B O, ZHAO Y M, et al.Integrinβ1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway[J].Oncol Lett,2016,11(1):535.

[33]FERRARA M G,MARTINI M,D'ARGENTO E,et al.PTEN loss as a predictor of tumor heterogeneity and poor prognosis in patients with EGFR-mutant advanced non-small-cell lung cancer receiving tyrosine kinase inhibitors[J].Clin Lung Cancer,2021,22(4):351.

[34]MASSARELLI E,VARELLA-GARCIA M,TANG X M,et al.KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].Clin Cancer Res,2007,13(10):2890.

[35]LU Y,LIU L,WANG Y,et al.siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells[J].Biomaterials,2016,76:196.

[36]NEGRAO M V,RAYMOND V M,LANMAN R B,et al.Molecularlandscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600driver mutations[J].J Thorac Oncol,2020,15(10):1611.

[37]OHASHI K,SEQUIST L V,ARCILA M E,et al.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS,NRAS,or MEK1[J].Proc Natl Acad Sci USA,2012,109(31):2127.

[38]LUDOVINI V,BIANCONI F,PISTOLA L,et al.Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2011,6(4):707.

[39]LEE A F,CHEN M C,CHEN C J,et al.Reverse epithelialmesenchymal transition co ntributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells[J].PLoS One,2017,12(7):e0180383.

[40]HUANG J,LAN X W,WANG T, et al.Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC[J].Oncogene,2020,39(8):1739.

[41]PATHAK R,VILLAFLOR V M.Histologic transformation in EGFR-mutant lung adenocarcinomas:mechanisms and therapeutic implications[J].Cancers,2021,13(18):4641.

[42]OFFIN M,CHAN J M,TENET M,et al.Concurrent RB1 and TP53alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J].J Thorac Oncol,2019,14(10):1784.

[43]MORIYA R,HOKARI S,SHIBATA S,et al.Histological transformation to large cell neuroendocrine carcinoma from lung adenocarcinoma harboring an EGFR mutation:an autopsy case report[J].Intern Med,2017,56(15):2013.

[44]IZUMI H,YAMASAKI A,UEDA Y,et al.Squamous cell carcino ma transformation from EGFR-mutated lung adenocarcinoma:a case report and literature review[J].Clin Lung Cancer,2018,19(1):e63.

[45]HUANG Y T,DAI Y,WEN C J,et al.circSETD3 contributes to acquired resistance to gefitinib in non-small-cell lung cancer by targeting the miR-520h/ABCG2 pathway[J].Mol Ther Nucleic Acids,2020,21:885.

[46]ZHAO H B,HUANG Y T,SHI J J,et al.ABCC10 plays a significant role in the transport of gefitinib and contributes to acquired resistance to gefitinib in NSCLC[J].Front Pharmacol,2018,9:1312.

[47]ZHU V W,KLEMPNER S J,OU S H I.Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer[J].Trends Cancer,2019,5(11):677.

[48]VOJNIC M,KUBOTA D,KURZATKOWSKI C,et al.Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers[J].J Thorac Oncol,2019,14(5):802.

[49]XIA H,XUE X Y,DING H X,et al.Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+NSCLC:results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer[J].Clin Lung Cancer,2020,21(3):247.

[50]LIU L H,WANG C,LI S N,et al.Tumor immunemicroenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment:a narrative review[J].Transl Lung Cancer Res,2021,10(9):3823.

[51]PENG S L,WANG R,ZHANG X J,et al.EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1expression[J].Mol Cancer,2019,18(1):165.

[52]WU L L,KE L P,ZHANG Z S,et al.Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib:conventional ways and immune checkpoint inhibitors[7].Front Oncol,2020,10:602762.